Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure

Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure

Abstract The effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitor ertugliflozin on fluid volume and kidney function was assessed in patients with type 2 diabetes and heart failure. Thirty‐four participants were randomized in this double‐blind, placebo‐controlled, parallel‐group, multicenter st...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuliya Lytvyn, Rosalie A. Scholtes, Eva M. Boorsma, Vikas S. Sridhar, Luxcia Kugathasan, Hongyan Liu, Leif E. Lovblom, Louis Handoko, Charlotte M. Mosterd, John S. Floras, Kevin Burns, Tosin Osuntokun, Adriaan Voors, Daniel H. vanRaalte, Hiddo J. L. Heerspink, David Z. I. Cherney
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Physiological Reports
Subjects:
ertugliflozin
heart failure
SGLT2 inhibition
type 2 diabetes
Online Access:https://doi.org/10.14814/phy2.70275
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.14814/phy2.70275

Similar Items